Feighner J P, Herbstein J, Damlouji N
J Clin Psychiatry. 1985 Jun;46(6):206-9.
Patients with "treatment resistant" depression who do not respond to standard methods or relapse over time have a moral and legitimate right to innovative therapy. Combined treatment with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and stimulants has been resisted by practitioners because of hypertensive and hyperthermic crises noted in certain cases. This paper reports a case series demonstrating the safety and efficacy of adding a stimulant to an MAOI or to a combination of TCA and MAOI in the treatment of intractable depression.
对标准治疗方法无反应或随时间复发的“难治性”抑郁症患者有获得创新疗法的道德和合法权利。由于某些病例中出现高血压和高热危机,从业者一直抵制单胺氧化酶抑制剂(MAOIs)、三环类抗抑郁药(TCAs)和兴奋剂的联合治疗。本文报告了一系列病例,证明在治疗难治性抑郁症时,在MAOI或TCA与MAOI的联合用药中添加兴奋剂的安全性和有效性。